ENDRA Life Sciences Inc. NDRA 深 滬
已收盤 05-22 16:00:00 美东时间
5.46
+0.110
+2.06%
華盛通- 最 高5.55
- 今 開5.40
- 成交量 8038股
- 最 低 5.40
- 昨 收 5.35
- 總市值 693.46万
- 52周最高 11.96
- 市盈率 靜 --
- 換手率 0.63%
- 52周最低 2.96
- 委 比 -52.61%
- 總股本 127.01万
- 歷史最高 205800.00
- 量 比 0.36
- 振 幅 2.80%
- 歷史最低 2.90
- 每 手 1
- 風險率 1.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ENDRA Life Sciences Q1 EPS $(1.09) Beats $(1.14) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.14) by 4.39 percent. This is a 41.4 percent increase over losses of $(1.86) per share from
05-18 20:04
ENDRA Life Sciences Reports Multi-Site Validation And MRI-Level Accuracy Of TAEUS Liver Device
The analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independent operators and patient populations. TAEUS Liver's thermoacoustic fat
05-14 20:09
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Immutep (NASDAQ:IMMP) shares rose 135.4% to $0.74 during Wednesday's p...
04-15 20:05
ENDRA Life Sciences Q4 EPS $(3.25) Misses $(1.95) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(3.25) per share which missed the analyst consensus estimate of $(1.95) by 66.67 percent. This is a 55.78 percent increase over losses of $(7.35) per share
04-01 05:22
ENDRA Life Sciences Says On March 19 , Reduced Number Of Employees In Order To Reduce Cash Expenditures And Extend Its Operational Runway; Expects To Incur Pre-Tax Cash Charges Of ~$51,000 Associated With Severance Payments To Former Employees
Costs Associated with Exit or Disposal Activities. On March 25, 2026, ENDRA Life Sciences Inc. (the "Company") announced that it has initiated a process to evaluate a range of strategic alternatives aimed at
03-25 21:28
Why AMTD Digital Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
AMTD Digital Inc - ADR (NYSE: HKD) jumped 24.4% in pre-market trading after reporting a 565.7% increase in FY25 revenue results to $136.1 million.
03-02 17:26
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
ENDRA Life Sciences Announces New Results From 2025 TAEUS Liver Device Feasibility Study Showing TAEUS' TAFF Measurement Closely Tracks MRI-PDFF Gold Standard At Critical LFF Thresholds Of 12-17% And 20-22%
Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoringENDRA Life Sciences Inc. (NASDAQ:NDRA)
2025-12-04 21:03
ENDRA Life Sciences Reports TAEUS Device Matches MRI Accuracy in Liver Disease Study
ENDRA Life Sciences Inc. has announced new results from a recently completed feasibility study of its TAEUS® Liver device, designed for the early detection and monitoring of steatotic liver disease (S...
2025-12-04 21:01
ENDRA Life Sciences Q3 EPS $(2.10) Misses $(1.95) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(2.10) per share which missed the analyst consensus estimate of $(1.95) by 7.69 percent. This is a 77.99 percent increase over losses of $(9.54) per share
2025-11-17 21:20
